Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission.

医学 文 内科学 威尼斯人 耐受性 阿糖胞苷 阿扎胞苷 肿瘤科 髓系白血病 外科 胃肠病学 白血病 不利影响 慢性淋巴细胞白血病 基因表达 DNA甲基化 化学 基因 生物化学 计算机科学 计算机安全
作者
Alexandre Bazinet,Hagop M. Kantarjian,Gautam Borthakur,Musa Yılmaz,Prithviraj Bose,Elias Jabbour,Yesid Alvarado Valero,Kelly S. Chien,Naveen Pemmaraju,Koichi Takahashi,Ghayas C. Issa,Nitin Jain,Debra Bull-Linderman,Courtney D. DiNardo,Guillermo Garcia‐Manero,Koji Sasaki,Farhad Ravandi,Tapan M. Kadia
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): e19018-e19018 被引量:1
标识
DOI:10.1200/jco.2022.40.16_suppl.e19018
摘要

e19018 Background: Most patients (pts) with AML achieve remission with current therapies but rates of relapse are high. Maintenance with oral AZA (CC-486) has been shown to prolong overall survival (OS) and relapse-free survival (RFS) in SCT-ineligible patients with AML in remission. The addition of VEN to maintenance regimens should be explored. Methods: We designed a phase 2, single-center, single-arm study to evaluate the efficacy and tolerability of AZA + VEN maintenance in AML. Pts ≥ 18 years in first remission (CR1) after induction and 1+ consolidations not immediately eligible for SCT were treated with AZA 50 mg/m2 IV/SQ on D1-5 and VEN 400 mg on D1-14 (or D1-7 at physician discretion) every 28 days, up to 24 cycles. Pts in CR2 and beyond were eligible if positive for minimal residual disease (MRD). Both intensive (INT; int/high dose cytarabine-based) and low-intensity (LOW; HMA/LDAC-based) induction regimens were permitted, including prior VEN. The primary outcome was modified RFS (mRFS; enrollment to relapse or death). Key secondary objectives were OS (enrollment to death), safety, and MRD clearance. Results: As of Feb 10 2022, 33 pts have been enrolled (characteristics in Table). The median number of cycles given is 6 (range 1-23). 20 pts (61%) received 7 days and 13 (39%) received 14 days of VEN. To date, 8 relapses and 6 deaths (all after relapse or SCT) have occurred. 5 pts (15%) have gone off protocol for SCT (censored at time of SCT). Median mRFS is not reached (NR) in both the INT and LOW cohorts (1-yr mRFS 73.9% and 58.3%, respectively). When stratified by ELN 2017, mRFS was NR, NR, and 4 mo for favorable, intermediate, and adverse risk, respectively (6-mo mRFS 92.3%, 90%, and 44.4%). Median OS is NR in both the INT and LOW cohorts (1-yr OS 93.8% and 53.3%, respectively). mRFS was numerically higher in pts with VEN exposure as part of their induction regimen (1-yr mRFS 79.1% vs 55.6% in non-VEN-exposed pts, p=0.067). Of the 7 MRD(+) pts at enrollment, 2 (29%) cleared their MRD on AZA/VEN maintenance. MRD(+) pts had a median mRFS of only 4 mo compared to NR in the MRD(-) pts (p=0.001). The MRD(+) pts in our study were very high risk (5/7 ELN adverse, 3/7 complex karyotype). The most common grade 3/4 AEs were infections (18%), thrombocytopenia (15%), neutropenia (12%), and neutropenic fever (6%). 4/33 pts (12%) required C2 VEN dose reduction for cytopenias. Conclusions: AZA/VEN maintenance is effective and tolerable in AML pts not immediately eligible for SCT after intensive or low-intensity induction. The regimen yields encouraging mRFS and OS durations. Longer follow-up and comparative studies are needed to confirm these initial results. Clinical trial information: NCT04062266. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
紫烨完成签到,获得积分10
刚刚
刚刚
张菜菜发布了新的文献求助10
刚刚
慕青的应助被明颜采纳,获得10
1秒前
美好觅松发布了新的文献求助10
1秒前
XXxx完成签到,获得积分10
1秒前
2秒前
香蕉觅云的应助被ttxxcdx采纳,获得10
2秒前
少东瓜完成签到,获得积分10
2秒前
Tracy完成签到,获得积分10
3秒前
单薄剑愁完成签到,获得积分10
3秒前
sci完成签到 ,获得积分10
3秒前
3秒前
Shawn发布了新的文献求助10
4秒前
4秒前
cc发布了新的文献求助30
5秒前
5秒前
6秒前
6秒前
molihuakai的应助被桀桀桀采纳,获得10
7秒前
Nole的应助被逸一时误一世采纳,获得10
8秒前
Mario发布了新的文献求助10
9秒前
fff发布了新的文献求助10
9秒前
9秒前
10秒前
哈哈哈给哈哈哈的求助进行了留言
11秒前
若愚发布了新的文献求助10
11秒前
11秒前
光亮雨发布了新的文献求助10
11秒前
mwzz233完成签到,获得积分10
12秒前
Ava的应助被xxxx采纳,获得10
12秒前
13秒前
无花果的应助被Mario采纳,获得10
14秒前
15秒前
沉静寄容完成签到,获得积分10
16秒前
雨夜发布了新的文献求助10
16秒前
哈哈完成签到,获得积分10
16秒前
vghsgf发布了新的文献求助10
16秒前
wangzy完成签到,获得积分10
16秒前
aaairplane发布了新的文献求助20
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171409
求助须知:如何正确求助?哪些是违规求助? 9564142
关于积分的说明 21773764
捐赠科研通 7762987
什么是DOI,文献DOI怎么找? 3430922
关于科研通互助平台的介绍 2554785
邀请新用户注册赠送积分活动 2475852